AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast cancer – the first drug in the class to show that in a clinical trial.

AstraZeneca and Merck & Co’s partnership to develop ovarian cancer drug Lynparza has got off to a good start after the FDA approved its use in a wider group of women. The drug has been approved ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...